Thymalin Research: Human Trials, Gene Expression Data & What the Studies Show
Modern research-grade Thymalin is a synthetic peptide complex that mirrors the short polypeptide fractions originally characterised at the Khavinson Institute of Bioregulation and Gerontology in St. Petersburg. The published literature covers in-vitro stem cell assays, epigenetic gene expression mapping, animal tumour studies and decades of human clinical tracking.
Mechanism of action
Modern Thymalin is a synthetic peptide complex modelled on the short polypeptide fractions originally isolated from thymus tissue. It acts as an immunomodulator and epigenetic regulator rather than a single synthetic sequence.
Its core active components are short, ultrashort dipeptides — KE and EW (known commercially as Thymogen) — small enough to cross cell membranes and bind directly to double-stranded DNA.
By binding DNA and 'unwrapping' specific regions (deheterochromatinisation), the peptides alter gene expression, switching on protective antioxidant and anti-inflammatory protein synthesis and steering immune-cell maturation.
The studies
Each study below states the benefit that was tested, then what the data showed. Note that Thymalin's evidence base mixes in-vitro cell assays, animal survival studies and long-running Soviet-era and Russian human clinical cohorts.
Immune cell biology
In vitro hematopoietic stem cell differentiation
Benefit tested: can Thymalin force raw human bone marrow stem cells to mature into specialised antiviral T-lymphocytes?
Human hematopoietic stem cells (HSCs) isolated and exposed directly to Thymalin in culture · stem cell and T-cell surface marker tracking
- Down 2-3×
- CD44 / CD117 (stem markers)
- Up 6.8×
- CD28 (mature T-lymphocyte)
- Direct cell exposure
- Delivery
Benefits shown in the data
- Acted as a cellular instruction manual, pushing primitive stem cells toward mature immune-cell fates.
- Reduced embryonic stem cell markers CD44 and CD117 by 2-3 times, showing cells leaving the undifferentiated state.
- Increased CD28 — the marker of mature antiviral T-lymphocytes — by 6.8 times, evidence of rapid immune-cell maturation.
- This is an in-vitro assay: cells in a dish, not a living immune system.
- It provides the mechanistic basis for why Thymalin is studied in age-related and infection-driven T-cell depletion.
- Marker expression changes are a proxy for function; downstream antiviral activity needs separate confirmation.
Epigenetics & inflammation
Epigenetic overhaul and gene expression (COVID-19 focus)
Benefit tested: can the short peptides inside Thymalin bind DNA and switch off the genes driving hyper-inflammatory cytokine storms and vascular damage?
Molecular modelling and transcriptome sequencing tracking the constituent dipeptides KE and EW inside cells · gene expression mapping
- Downregulated
- ACE2 gene
- Downregulated
- CYSLTR1 gene
- Normalised
- Cytokine output
Benefits shown in the data
- Short peptides physically cross cell membranes and bind double-stranded DNA, unwrapping specific gene regions.
- Downregulated ACE2 and CYSLTR1 — the receptor landing pads for SARS-CoV-2 and hyper-inflammatory leukotriene responses.
- Normalised cytokine output and protected blood vessels from endothelium-dependent damage.
- The work is molecular and transcriptomic — it maps gene targets rather than measuring clinical outcomes in patients.
- It explains the proposed anti-inflammatory mechanism at genetic level rather than through receptor blockade alone.
- Extrapolating gene expression shifts to infection outcomes requires controlled clinical trials.
Oncology & inflammaging
Restraining age-associated cancer progression
Benefit tested: can restoring youthful thymic signalling calm myeloid-driven 'inflammaging' and let the immune system attack tumours again?
Aged animal models with aggressive tumours · daily subcutaneous injections of thymic peptide · tumour progression and tumour-infiltrating T-cell function
- Delayed
- Tumour progression
- Restored
- IFN-γ production
- Unchanged
- Effect in young subjects
Benefits shown in the data
- Restrained age-associated myeloid inflammation, the chronic low-grade state that exhausts T-cells.
- Delayed tumour progression in aged subjects receiving systemic subcutaneous injections.
- Restored tumour-infiltrating T-cells' ability to produce Interferon-gamma (IFN-γ), breaking through tumour defences.
- The benefit was strictly age-dependent: profound in old subjects, with young healthy baselines unchanged.
- This is animal data — it does not establish any anticancer effect in humans.
- It supports the 'inflammaging' model in which thymic decline, not the tumour alone, drives progression.
Longevity & human clinical data
Comprehensive clinical review & 30-year survival metrics
Benefit tested: does cyclical Thymalin dosing slow biological aging, prevent respiratory disease and extend human lifespan?
Decades of human clinical tracking · standard historical courses of ~10 mg intramuscular or subcutaneous Thymalin in annual cycles · elderly cohorts versus untreated controls
- Normalised
- T-cell immunity
- Sharply decreased
- Acute respiratory infections
- Significantly reduced
- Mortality (elderly cohorts)
Benefits shown in the data
- Normalised basic T-cell immunity in elderly patients whose thymic output had declined.
- Stabilised blood coagulation systems alongside immune markers.
- Sharply decreased the incidence of acute respiratory infections.
- Multi-decade tracking showed a highly significant reduction in mortality versus untreated control groups.
- This is a historical overview of long-running cohorts, not a modern randomised double-blind trial.
- Much of the underlying data comes from Soviet-era and Russian clinical practice, with limited independent Western replication.
- It is the primary basis for Thymalin's description as a geroprotector in the literature.
Storage & handling
Thymalin is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water added slowly down the inner wall of the vial; swirl gently until fully dissolved and never shake — peptide complexes are shear-sensitive.
Store reconstituted solution at 2-8 °C, protect from light, and use within your lab's defined stability window. Avoid repeated freeze-thaw cycles.
The delivery reality: sub-Q injection vs. nasal sprays
Historical trials heavily favoured intramuscular or subcutaneous injection to get the full polypeptide complex into circulation. Modern research has adapted by isolating the ultrashort dipeptide fragments for intranasal delivery.
| Route | Why it is used | What the literature reports |
|---|---|---|
| Subcutaneous / intramuscular | Delivers the full polypeptide complex systemically; the route used in nearly all historical human trials. | Favoured for system-wide immunomodulation, chronic infection work and longevity protocols because absorption is consistent and systemic. |
| Intranasal (dipeptide fragments) | The isolated EW dipeptide / Thymogen fragment is only two amino acids long, so it penetrates nasal mucosa without a needle. | Studied for rapid bronchoprotection, clearing localised upper-respiratory inflammation and modulating systemic white blood cell counts. |
Research use only
Thymalin is not an approved therapy for aging, cancer, immune deficiency or respiratory infection in South Africa or most jurisdictions. All material supplied here is strictly for laboratory research and is not for human or veterinary use.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.